Verve Therapeutics downgraded to Hold from Buy at Canaccord

finance.yahoo.com/news/verve-therapeutics-downgraded-hold-buy-135531371.html

In This Article:
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a…

This story appeared on finance.yahoo.com, 2025-06-18 13:55:31.
The Entire Business World on a Single Page. Free to Use →